Media ReleasesCircadian

View All Circadian News

Circadian receives FDA IND approval to begin clinical trials with VGX-100 for the treatment of cancer patients with solid tumors

Melbourne, Australia October 31, 2011 – Circadian Technologies Limited (ASX: CIR, OTCQX:CKDXY) announces that its 100% owned subsidiary, Vegenics Pty Ltd, has received approval for its investigational new drug (IND) application from the U.S. Food and Drug  Administration (FDA) to initiate clinical trials of VGX-100. The first trial (Phase I) will study VGX-100 in patients with a variety of late stage cancers.

For further information please download PDF below:

Download this document